---
document_datetime: 2025-10-14 15:06:58
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abrysvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: abrysvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7506598
conversion_datetime: 2025-12-28 04:50:41.011435
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Abrysvo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 04/09/2025                          |                                             | SmPC                             | The safety and immunogenicity of Abrysvo have |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000254927                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update clinical efficacy and safety information on the use of Abrysvo in immunocompromised individuals, based on final results from Study C3671023 (substudy B); this is a Phase 3 clinical study designed to evaluate the safety, tolerability, and immunogenicity of Abrysvo in adults at high risk of severe RSV disease. Substudy B was conducted in approximately 200 immunocompromised participants who were 18 years of age and older and received 2 doses of RSVpreF 120 µg, with an interval of 1 month. The RMP version 2.0 has also been approved. In addition, the MAH took the opportunity to introduce a minor change to the PI.   |            |          | been assessed in immunocompromised individuals 18 years of age and older, including those receiving immunosuppressant therapy. The efficacy of Abrysvo may be lower in immunosuppressed individuals. Study 4 (C3671023 Substudy B) was a Phase3, single -arm, open-label, multicentre study to assess the safety and immunogenicity of Abrysvo in immunocompromised individuals ≥18years of age. Participants had history of a solid organ transplant (kidney, liver, lung or heart) at least 3months prior to enrollment; en d stage renal disease and on haemodialysis; autoimmune inflammatory disorders with active immunomodulator therapy; or advanced non-small cell lung cancer and receiving active immunomodulator therapy. Participants received 2doses of Abrysvo with an interval of 1month. A single dose of Abrysvo was sufficient to elicit robust neutralising responses approximately 8- or 9- fold above baseline against RSVA and RSVB in participants ≥18years of age with immunocompromising conditions (n=188). Responses did not further increase with a second dose of Abrysvo 1month after the first dose. Reactogenicity was consistent with the known profile of Abrysvo. There were no unexpected safety findings.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000280293 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/09/2025 | Annex II | Annex II is updated to clarify the name of an already approved site.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                       | in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place -   |            |      |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000286922 | This was an application for a group of variations. B.I ACTIVE SUBSTANCE - B.I.z Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/08/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

|                                       | variation - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000276458 | This was an application for a group of variations. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Change in supplier of sterilised primary container components,                                                                                                                                            | 08/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | which are to be used in the aseptic manufacture of medicinal products - Accepted                         |            |     |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000248438 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.z Other variation - Accepted | 04/03/2025 | N/A |             |
| PSUR / EMA/PSUR/0000257789            | - -                                                                                                      |            |     | Maintenance |